India Pesticides FY26: A ₹1,078 Crore Topline with a Side of Subsidiary Drama

Section 1 — At a Glance

A structural recovery in volume growth has redefined the financial trajectory for India Pesticides Limited in the full year ended March 31, 2026. Driven primarily by an aggressive domestic market pull-through and structural normalization of international channel inventories, the company has breached a critical scale threshold, reporting an annual revenue of ₹1,078 crore. This volume-led expansion represents a 27.9% year-on-year topline growth, allowing operating efficiencies to offset stubborn raw material pricing pressures emanating from global supply corridors.

While the headline metrics point to an accelerating recovery, deep-seated structural vulnerabilities continue to demand cautious analytical scrutiny. Operating cash flow conversion remains structurally constrained by an inherently elongated working capital cycle, which finished the year at 223 days. This capital intensification is structurally driven by a competitive market shift toward spot-basis procurement, forcing the entity to carry elevated buffer inventories. Furthermore, execution risks are shifting toward the company’s capital work-in-progress, which currently stands at ₹68 crore. The bulk of this capital is locked inside the unseasoned wholly owned subsidiary, Shalvis Specialities Limited, which contributed a nominal ₹4 crore to the FY26 topline and faces an aggressive ramp-up schedule into FY27. Sustainable long-term capital returns remain entirely contingent on the operational stabilization of these new specialty manufacturing blocks, balanced against seasonal capacity utilization limits in the core herbicide intermediates segment.

Section 2 — Introduction

India Pesticides Limited (IPL) has traveled a long road from its 1984 origins to its current status as a publicly traded agrochemical operator. The company specializes in the synthesis of generic agrochemical technicals, formulations, and a tiny sliver of active pharmaceutical ingredients (APIs) focused on dermatological applications. Over the decades, management has successfully carved out niche global market shares in specific off-patent molecules. However, operating in the agrochemical universe means surviving a perpetual gauntlet of raw material volatility, erratic monsoons, and the unpredictable pricing whims of Chinese dumpers. The fiscal year 2026 marks a period where IPL attempted to build structural defensive walls against these external shocks through domestic capacity expansion and backward integration.

Section 3 — Business Model: WTF Do They Even Do?

To put it bluntly, India Pesticides makes the chemical ammunition that farmers use to wage war against bugs, weeds, and fungi. Their business is divided into Technicals (the raw bulk active ingredients) and Formulations (the final packaged chemical cocktails you actually spray on a field). They proudly claim to be the sole Indian manufacturer and a top-five global producer for several Technicals like Folpet and Thiocarbamate herbicides.

The corporate architecture relies on two main manufacturing hubs in Uttar Pradesh—Lucknow and Sandila. Lucknow is the boutique unit doing 2,100 MTPA of technicals, while Sandila is the heavy lifter with 26,100 MTPA of technical capacity. While they sell across 18 Indian states, exports to 35+ countries consistently make up around 39% to 41% of their revenue mix. In short, they manufacture chemical molecules at scale, try to sell them to multinational corporations before China crashes the global price party, and use an army of 350+ sales personnel to push formulations directly into the domestic rural landscape.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

The final quarter of FY26 was an energetic sprint, with revenue landing at ₹271 crore, outstripping the ₹211 crore from the same period last year. Profit after tax surged by 40.6% year-on-year to ₹31 crore. Earnings quality is fundamentally a reflection of revenue predictability, and when a business shifts from contractual planning to spot orders, short-term earnings volatility inevitably rises.

What is Management Promising in the Coming Quarters?

During the May 2026 earnings call, the CEO didn’t hold back on optimism, confidently forecasting a 15% to 20% revenue expansion for FY27. Management called the 18% EBITDA margin baseline structural, with the CFO indicating that their newly commissioned backward-integration facility for herbicide intermediates (PEDA/Pretilachlor) will act as an insurance policy against raw material spikes. For